A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
Latest Information Update: 17 May 2023
At a glance
- Drugs Zilurgisertib (Primary)
- Indications Anaemia; Fibrodysplasia ossificans progressiva; Myelofibrosis; Renal failure; Renal impairment
- Focus Pharmacokinetics
- Sponsors Incyte Corporation
- 12 May 2023 Status changed from recruiting to completed.
- 14 Mar 2022 Planned End Date changed from 8 Dec 2022 to 6 Jan 2023.
- 05 Jan 2022 Status changed from not yet recruiting to recruiting.